News | May 27, 2025
Akums reports Q4 FY25 with 12.4% revenue growth
Akums invested Rs. 272 crore in capital expenditure during FY25
Akums invested Rs. 272 crore in capital expenditure during FY25
R&D spend for Q4 was Rs. 50.3 crore, 4.9 per cent of Q4?revenue
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
For the full year FY25, net profit soared 12x to Rs 345 crore
Q4 FY25 PAT stood at Rs. 90.7 crore as compared to Rs.77.6 crore in Q4 FY24
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
The company has posted net profit of Rs. 91.13 crores for the Financial Year ended March 31, 2025
EBITDA before special items decreases to €4.08 billion (7.4%)
_256_384.jpg)
The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
Subscribe To Our Newsletter & Stay Updated
